{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T12:30:23Z","timestamp":1777552223820,"version":"3.51.4"},"reference-count":37,"publisher":"Georg Thieme Verlag KG","issue":"03","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Liver Dis"],"published-print":{"date-parts":[[2019,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>New treatments for primary biliary cholangitis (PBC) are progressively emerging, including first and second generations of farnesoid X receptor and peroxisome proliferator-activated receptors agonists. Even though ursodeoxycholic acid monotherapy remains the standard of care treatment for PBC, these additional therapeutic options, already or soon to be available, lead us to revise our priorities and strategies with respect to future clinical trials. The present article is a personal view of where we currently stand in this field and where and how we should be going to achieve new progress.<\/jats:p>","DOI":"10.1055\/s-0039-1687852","type":"journal-article","created":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:34:41Z","timestamp":1556670881000},"page":"e1-e6","source":"Crossref","is-referenced-by-count":3,"title":["Clinical Trials in PBC Going Forward"],"prefix":"10.1055","volume":"39","author":[{"given":"Christophe","family":"Corpechot","sequence":"additional","affiliation":[{"name":"Reference Center for Inflammatory Biliary Diseases and Autoimmune Hepatitis (MIVB-H), French Network for Pediatric and Adult Rare Liver Diseases (FILFOIE), Saint-Antoine Hospital, Assistance Publique \u2013 H\u00f4pitaux de Paris (APHP) and Sorbonne University, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2019,4,30]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"S214","DOI":"10.1016\/S0168-8278(18)30644-5","article-title":"Time trends in liver transplantation for primary biliary cholangitis in Europe over the past three decades","volume":"68","author":"M H Harms","year":"2018","journal-title":"J Hepatol"},{"issue":"07","key":"ref2","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"F Nevens","year":"2016","journal-title":"N Engl J Med"},{"issue":"23","key":"ref3","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","article-title":"A placebo-controlled trial of bezafibrate in primary biliary cholangitis","volume":"378","author":"C Corpechot","year":"2018","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1016\/S0168-8278(18)30426-4","article-title":"Early assessment of safety and efficacy of tropifexor, a potent non bile-acid FXR agonist, in patients with primary biliary cholangitis: an interim analysis of an ongoing phase 2 study","volume":"68","author":"C Schramm","year":"2018","journal-title":"J Hepatol"},{"issue":"10","key":"ref5","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S2468-1253(17)30246-7","article-title":"Seladelpar (MBX-8025), a selective PPAR-\u03b4 agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study","volume":"2","author":"D Jones","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"22","key":"ref6","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1056\/NEJM199105303242204","article-title":"A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis","volume":"324","author":"R E Poupon","year":"1991","journal-title":"N Engl J Med"},{"issue":"05","key":"ref7","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/hep.1840190512","article-title":"The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis","volume":"19","author":"E J Heathcote","year":"1994","journal-title":"Hepatology"},{"issue":"05","key":"ref8","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/0016-5085(94)90021-3","article-title":"Ursodeoxycholic acid in the treatment of primary biliary cirrhosis","volume":"106","author":"K D Lindor","year":"1994","journal-title":"Gastroenterology"},{"issue":"03","key":"ref9","first-page":"759","article-title":"A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis","volume":"22","author":"B Combes","year":"1995","journal-title":"Hepatology"},{"issue":"04","key":"ref10","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0168-8278(00)80216-0","article-title":"Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial","volume":"32","author":"A Par\u00e9s","year":"2000","journal-title":"J Hepatol"},{"issue":"01","key":"ref11","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis","volume":"67","year":"2017","journal-title":"J Hepatol"},{"issue":"09","key":"ref12","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1136\/gutjnl-2017-315259","article-title":"The British Society of Gastroenterology\/UK-PBC primary biliary cholangitis treatment and management guidelines","volume":"67","author":"G M Hirschfield","year":"2018","journal-title":"Gut"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30145","article-title":"Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases","volume":"\u2022\u2022\u2022","author":"K D Lindor","year":"2018","journal-title":"Hepatology"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/s41395-018-0390-3","article-title":"Diagnosis and management of primary biliary cholangitis","volume":"\u2022\u2022\u2022","author":"Z M Younossi","year":"2018","journal-title":"Am J Gastroenterol"},{"issue":"03","key":"ref15","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/hep.22428","article-title":"Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis","volume":"48","author":"C Corpechot","year":"2008","journal-title":"Hepatology"},{"issue":"03","key":"ref16","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","article-title":"Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid","volume":"130","author":"A Par\u00e9s","year":"2006","journal-title":"Gastroenterology"},{"issue":"04","key":"ref17","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1053\/j.gastro.2009.01.003","article-title":"Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid","volume":"136","author":"E M Kuiper","year":"2009","journal-title":"Gastroenterology"},{"issue":"10","key":"ref18","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1038\/ajg.2010.216","article-title":"Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis","volume":"105","author":"T Kumagi","year":"2010","journal-title":"Am J Gastroenterol"},{"issue":"06","key":"ref19","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.jhep.2011.02.031","article-title":"Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome","volume":"55","author":"C Corpechot","year":"2011","journal-title":"J Hepatol"},{"issue":"04","key":"ref20","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1872-034X.2011.00782.x","article-title":"Biochemical response to ursodeoxycholic acid predicts long-term outcome in Japanese patients with primary biliary cirrhosis","volume":"41","author":"N Azemoto","year":"2011","journal-title":"Hepatol Res"},{"issue":"07","key":"ref21","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1053\/j.gastro.2015.07.061","article-title":"Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy","volume":"149","author":"W J Lammers","year":"2015","journal-title":"Gastroenterology"},{"issue":"03","key":"ref22","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1002\/hep.28017","article-title":"The UK-PBC risk scores: derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis","volume":"63","author":"M Carbone","year":"2016","journal-title":"Hepatology"},{"issue":"03","key":"ref23","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1053\/j.gastro.2012.12.005","article-title":"Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid","volume":"144","author":"M Carbone","year":"2013","journal-title":"Gastroenterology"},{"issue":"06","key":"ref24","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1053\/j.gastro.2014.08.029","article-title":"Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study","volume":"147","author":"W J Lammers","year":"2014","journal-title":"Gastroenterology"},{"key":"ref25","first-page":"1445A","article-title":"Efficacy and safety of Seladelpar, a selective peroxisome proliferator-activated receptor delta agonist, in primary biliary cholangitis: 52-week analysis of an ongoing international, randomized, dose ranging phase 2 study","volume":"68","author":"C Bowlus","year":"2018","journal-title":"Hepatology"},{"issue":"09","key":"ref26","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/hep4.1209","article-title":"NGM282 for treatment of patients with primary biliary cholangitis: a multicenter, randomized, double-blind, placebo-controlled trial","volume":"2","author":"M J Mayo","year":"2018","journal-title":"Hepatol Commun"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/S0168-8278(18)30293-9","article-title":"Results of a randomised controlled trial of budesonide add-on therapy in patients with primary biliary cholangitis and an incomplete response to ursodeoxycholic acid","volume":"68","author":"G Hirschfield","year":"2018","journal-title":"J Hepatol"},{"issue":"04","key":"ref28","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S0016-5085(99)70351-3","article-title":"Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial","volume":"117","author":"M Leuschner","year":"1999","journal-title":"Gastroenterology"},{"issue":"04","key":"ref29","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/hep.20646","article-title":"Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial","volume":"41","author":"H Rautiainen","year":"2005","journal-title":"Hepatology"},{"issue":"03","key":"ref30","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jhep.2017.05.009","article-title":"norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis","volume":"67","author":"P Fickert","year":"2017","journal-title":"J Hepatol"},{"issue":"01","key":"ref31","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1055\/s-0035-1571273","article-title":"Primary biliary cirrhosis beyond ursodeoxycholic acid","volume":"36","author":"C Corpechot","year":"2016","journal-title":"Semin Liver Dis"},{"issue":"01","key":"ref32","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/hep.25599","article-title":"Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis","volume":"56","author":"C Corpechot","year":"2012","journal-title":"Hepatology"},{"issue":"05","key":"ref33","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1002\/hep.22517","article-title":"Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay","volume":"48","author":"M J Mayo","year":"2008","journal-title":"Hepatology"},{"issue":"01","key":"ref34","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/hep.27069","article-title":"Evolution of noninvasive tests of liver fibrosis is associated with prognosis in patients with chronic hepatitis C","volume":"60","author":"J Vergniol","year":"2014","journal-title":"Hepatology"},{"issue":"01","key":"ref35","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jhep.2015.04.006","article-title":"EASL-ALEH Clinical Practice Guidelines: non-invasive tests for evaluation of liver disease severity and prognosis","volume":"63","year":"2015","journal-title":"J Hepatol"},{"issue":"09","key":"ref36","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S2468-1253(18)30163-8","article-title":"Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score","volume":"3","author":"M Carbone","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref37","first-page":"1085A","article-title":"Alkaline phosphatase normalization is associated with a decreased risk for liver transplantation and death in patients with primary biliary cholangitis","volume":"68","author":"C F Murillo Perez","year":"2018","journal-title":"Hepatology"}],"container-title":["Seminars in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0039-1687852.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T22:58:46Z","timestamp":1597359526000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0039-1687852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,30]]},"references-count":37,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2019,8,2]]},"published-print":{"date-parts":[[2019,7]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0039-1687852","relation":{},"ISSN":["0272-8087","1098-8971"],"issn-type":[{"value":"0272-8087","type":"print"},{"value":"1098-8971","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,30]]}}}